Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency

SAN DIEGO, Dec. 26, 2017 -- (Healthcare Sales & Marketing Network) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation for the Company’s treatment of alpha... Regenerative Medicine, FDA Organovo, NovoTissues, alpha-1 antitrypsin deficiency

Source: HSMN NewsFeed - December 26, 2017 Category: Pharmaceuticals Source Type: news